AR095032A1 - Formulaciones de compuestos orgánicos, composición farmacéutica sólida comprimida por rodillo - Google Patents
Formulaciones de compuestos orgánicos, composición farmacéutica sólida comprimida por rodilloInfo
- Publication number
- AR095032A1 AR095032A1 ARP140100730A ARP140100730A AR095032A1 AR 095032 A1 AR095032 A1 AR 095032A1 AR P140100730 A ARP140100730 A AR P140100730A AR P140100730 A ARP140100730 A AR P140100730A AR 095032 A1 AR095032 A1 AR 095032A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutical composition
- solid pharmaceutical
- roller
- formulations
- composition compressed
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 5
- 239000007787 solid Substances 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title 1
- 150000002894 organic compounds Chemical class 0.000 title 1
- CWHUFRVAEUJCEF-UHFFFAOYSA-N BKM120 Chemical compound C1=NC(N)=CC(C(F)(F)F)=C1C1=CC(N2CCOCC2)=NC(N2CCOCC2)=N1 CWHUFRVAEUJCEF-UHFFFAOYSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 abstract 2
- 239000008187 granular material Substances 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 229940045902 sodium stearyl fumarate Drugs 0.000 abstract 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- MHQJUHSHQGQVTM-HNENSFHCSA-N Octadecyl fumarate Chemical compound CCCCCCCCCCCCCCCCCCOC(=O)\C=C/C(O)=O MHQJUHSHQGQVTM-HNENSFHCSA-N 0.000 abstract 1
- 108091007960 PI3Ks Proteins 0.000 abstract 1
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 abstract 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229910052708 sodium Inorganic materials 0.000 abstract 1
- 239000011734 sodium Substances 0.000 abstract 1
- 229940071138 stearyl fumarate Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B17/12—Surgical instruments, devices or methods for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord
- A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
- A61B17/12131—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device
- A61B17/12136—Balloons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B17/12—Surgical instruments, devices or methods for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord
- A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
- A61B17/12027—Type of occlusion
- A61B17/1204—Type of occlusion temporary occlusion
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B17/12—Surgical instruments, devices or methods for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord
- A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
- A61B17/12099—Occluding by internal devices, e.g. balloons or releasable wires characterised by the location of the occluder
- A61B17/12109—Occluding by internal devices, e.g. balloons or releasable wires characterised by the location of the occluder in a blood vessel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M25/1002—Balloon catheters characterised by balloon shape
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B17/12—Surgical instruments, devices or methods for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord
- A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
- A61B2017/1205—Introduction devices
- A61B2017/12054—Details concerning the detachment of the occluding device from the introduction device
- A61B2017/12068—Details concerning the detachment of the occluding device from the introduction device detachable by heat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B17/12—Surgical instruments, devices or methods for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord
- A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
- A61B2017/1205—Introduction devices
- A61B2017/12054—Details concerning the detachment of the occluding device from the introduction device
- A61B2017/12086—Details concerning the detachment of the occluding device from the introduction device magnetically detachable
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Surgery (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Medical Informatics (AREA)
- Vascular Medicine (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Inorganic Chemistry (AREA)
- Child & Adolescent Psychology (AREA)
- Pulmonology (AREA)
- Anesthesiology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Surgical Instruments (AREA)
Abstract
Composiciones farmacéuticas sólidas que comprenden el compuesto inhibidor de fosfatidilinositol 3-quinasa, 4-(trifluorometil)-5-(2,6-dimorfolinopirimidin-4-il)piridin-2-amina o una sal aceptable para uso farmacéutico del mismo, estearil fumarato de sodio, y opcionalmente al menos un vehículo aceptable para uso farmacéutico adicional. También se refiere a los procesos para su preparación y su uso como medicamentos para el tratamiento de cáncer. Reivindicación 1: Una composición farmacéutica sólida comprimida por rodillo que comprende (a) el compuesto 4-(trifluorometil)-5-(2,6-dimorfolinopirimidin-4-il)piridin-2-amina o una sal aceptable para uso farmacéutico del mismo, (b) estearil fumarato de sodio, y (c) opcionalmente al menos un vehículo aceptable para uso farmacéutico adicional. Reivindicación 4: La composición farmacéutica sólida comprimida por rodillo de acuerdo a cualquiera de las reivindicaciones precedentes, en donde la composición farmacéutica contiene una pluralidad de gránulos con una fase interna y una fase externa, y en donde dicha fase interna y fase externa de los gránulos ambas incluyen estearil fumarato de sodio.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361773492P | 2013-03-06 | 2013-03-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR095032A1 true AR095032A1 (es) | 2015-09-16 |
Family
ID=50342366
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140100730A AR095032A1 (es) | 2013-03-06 | 2014-03-06 | Formulaciones de compuestos orgánicos, composición farmacéutica sólida comprimida por rodillo |
| ARP230100279A AR128459A2 (es) | 2013-03-06 | 2023-02-06 | Composición farmacéutica sólida comprimida por rodillo y el proceso para su fabricación |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP230100279A AR128459A2 (es) | 2013-03-06 | 2023-02-06 | Composición farmacéutica sólida comprimida por rodillo y el proceso para su fabricación |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US9474534B2 (es) |
| EP (1) | EP2964200B1 (es) |
| JP (1) | JP6313343B2 (es) |
| KR (1) | KR102233757B1 (es) |
| CN (1) | CN105073099B (es) |
| AR (2) | AR095032A1 (es) |
| AU (1) | AU2014224238B2 (es) |
| BR (1) | BR112015021097B1 (es) |
| CA (1) | CA2904032C (es) |
| CL (1) | CL2015002466A1 (es) |
| EA (1) | EA028301B1 (es) |
| ES (1) | ES2634020T3 (es) |
| IL (1) | IL240579B (es) |
| JO (1) | JO3256B1 (es) |
| MA (1) | MA38358B1 (es) |
| MX (1) | MX370175B (es) |
| MY (1) | MY174648A (es) |
| NZ (1) | NZ711015A (es) |
| PE (1) | PE20151607A1 (es) |
| PH (1) | PH12015501945B1 (es) |
| PL (1) | PL2964200T3 (es) |
| PT (1) | PT2964200T (es) |
| SG (1) | SG11201506392VA (es) |
| TN (1) | TN2015000386A1 (es) |
| TW (1) | TW201442712A (es) |
| UA (1) | UA114948C2 (es) |
| WO (1) | WO2014136048A1 (es) |
| ZA (1) | ZA201505830B (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9498604B2 (en) | 1997-11-12 | 2016-11-22 | Genesis Technologies Llc | Medical device and method |
| US10335577B2 (en) | 2010-05-19 | 2019-07-02 | Nfinium Vascular Technologies, Llc | Augmented delivery catheter and method |
| US9561094B2 (en) | 2010-07-23 | 2017-02-07 | Nfinium Vascular Technologies, Llc | Devices and methods for treating venous diseases |
| EP3151904A4 (en) | 2014-06-04 | 2018-02-14 | Nfinium Vascular Technologies, LLC | Low radial force vascular device and method of occlusion |
| JP6914202B2 (ja) * | 2015-06-30 | 2021-08-04 | ジェネンテック， インコーポレイテッド | 薬物を含有する即放性錠剤及び錠剤の形成プロセス |
| FI130702B1 (en) * | 2018-12-18 | 2024-01-26 | Miikka Frant | Device suitable for insertion into the vein of a human patient |
| KR20220012891A (ko) * | 2019-05-24 | 2022-02-04 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 에스트로겐 수용체-알파 억제제의 경구 투여 형태로 암을 치료하는 방법 |
| WO2022066499A1 (en) * | 2020-09-27 | 2022-03-31 | Boston Scientific Scimed, Inc. | Expandable guide devices, systems, and methods |
| WO2022170187A1 (en) * | 2021-02-05 | 2022-08-11 | Pyne Devaraj | Detachable balloon embolization device and methods |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2232152C (en) * | 1995-12-27 | 2007-02-06 | Janssen Pharmaceutica N.V. | Bioadhesive solid dosage form |
| US5916235A (en) | 1997-08-13 | 1999-06-29 | The Regents Of The University Of California | Apparatus and method for the use of detachable coils in vascular aneurysms and body cavities |
| ES2343228T3 (es) * | 1998-02-10 | 2010-07-26 | Ethicon Endo-Surgery, Inc. | Aparato de oclusion, de anclaje, de tensionado o de direccion por flujo. |
| US6066157A (en) | 1998-09-16 | 2000-05-23 | Medtronics Ave, Inc. | Anchor joint for coaxial balloon dilatation catheter |
| US6368338B1 (en) | 1999-03-05 | 2002-04-09 | Board Of Regents, The University Of Texas | Occlusion method and apparatus |
| US7331973B2 (en) | 2002-09-30 | 2008-02-19 | Avdanced Cardiovascular Systems, Inc. | Guide wire with embolic filtering attachment |
| US7618435B2 (en) * | 2003-03-04 | 2009-11-17 | Nmt Medical, Inc. | Magnetic attachment systems |
| JO2660B1 (en) * | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| JP2012501971A (ja) * | 2008-09-03 | 2012-01-26 | バーテックス ファーマシューティカルズ インコーポレイテッド | 共結晶および共結晶を含む薬学的処方物 |
| TW201036957A (en) * | 2009-02-20 | 2010-10-16 | Astrazeneca Ab | Novel salt 628 |
| BR112012009496A2 (pt) * | 2009-10-23 | 2015-09-29 | Merck Sharp & Dohme | composição farmacêutica, e, método para tratar diabetes tipo 2 |
| US8992540B2 (en) | 2010-07-22 | 2015-03-31 | Kyphon Sarl | Adjustable surgical instruments and methods of use and fabrication |
| CA2816957A1 (en) * | 2010-11-07 | 2012-05-10 | Targegen, Inc. | Compositions and methods for treating myelofibrosis |
| EP3127492B1 (en) | 2011-06-03 | 2023-01-18 | Covidien LP | Embolic implant |
| WO2014164535A1 (en) | 2013-03-11 | 2014-10-09 | Ferry Steven J | A guidewire/ partial occluder for intraluminal travel |
-
2014
- 2014-03-04 CA CA2904032A patent/CA2904032C/en active Active
- 2014-03-04 JO JOP/2014/0069A patent/JO3256B1/ar active
- 2014-03-04 NZ NZ711015A patent/NZ711015A/en unknown
- 2014-03-04 PL PL14711613T patent/PL2964200T3/pl unknown
- 2014-03-04 BR BR112015021097-0A patent/BR112015021097B1/pt active IP Right Grant
- 2014-03-04 SG SG11201506392VA patent/SG11201506392VA/en unknown
- 2014-03-04 CN CN201480011950.2A patent/CN105073099B/zh active Active
- 2014-03-04 MA MA38358A patent/MA38358B1/fr unknown
- 2014-03-04 EA EA201591649A patent/EA028301B1/ru not_active IP Right Cessation
- 2014-03-04 MX MX2015011705A patent/MX370175B/es active IP Right Grant
- 2014-03-04 JP JP2015560827A patent/JP6313343B2/ja active Active
- 2014-03-04 EP EP14711613.1A patent/EP2964200B1/en active Active
- 2014-03-04 AU AU2014224238A patent/AU2014224238B2/en active Active
- 2014-03-04 WO PCT/IB2014/059424 patent/WO2014136048A1/en not_active Ceased
- 2014-03-04 PE PE2015001869A patent/PE20151607A1/es not_active Application Discontinuation
- 2014-03-04 KR KR1020157023903A patent/KR102233757B1/ko active Active
- 2014-03-04 US US14/771,908 patent/US9474534B2/en active Active
- 2014-03-04 UA UAA201508151A patent/UA114948C2/uk unknown
- 2014-03-04 PT PT147116131T patent/PT2964200T/pt unknown
- 2014-03-04 MY MYPI2015702599A patent/MY174648A/en unknown
- 2014-03-04 ES ES14711613.1T patent/ES2634020T3/es active Active
- 2014-03-05 TW TW103107542A patent/TW201442712A/zh unknown
- 2014-03-06 AR ARP140100730A patent/AR095032A1/es not_active Application Discontinuation
- 2014-03-10 US US14/774,775 patent/US10342547B2/en active Active
-
2015
- 2015-08-12 ZA ZA2015/05830A patent/ZA201505830B/en unknown
- 2015-08-13 IL IL240579A patent/IL240579B/en active IP Right Grant
- 2015-09-03 PH PH12015501945A patent/PH12015501945B1/en unknown
- 2015-09-03 TN TN2015000386A patent/TN2015000386A1/en unknown
- 2015-09-04 CL CL2015002466A patent/CL2015002466A1/es unknown
-
2023
- 2023-02-06 AR ARP230100279A patent/AR128459A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR095032A1 (es) | Formulaciones de compuestos orgánicos, composición farmacéutica sólida comprimida por rodillo | |
| CL2018000318A1 (es) | Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925) | |
| CL2018003681A1 (es) | Derivados de ácido borónico y usos terapéuticos de los mismos | |
| CR20150628A (es) | Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades | |
| DOP2015000274A (es) | Compuestos químicos | |
| NI201700011A (es) | 2-(morfolin-4-il)-1,7-naftiridinas. | |
| CO2018004857A2 (es) | Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer | |
| MX2015008628A (es) | Derivados de acido boronico y usos terapeuticos de los mismos. | |
| MX383686B (es) | Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn. | |
| BR112016015838A8 (pt) | compostos heterocíclicos aromáticos, composição farmacêutica compreendendo os referidos compostos e produto de combinação | |
| CL2013002417A1 (es) | Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas. | |
| DOP2015000170A (es) | Compuestos químicos | |
| SV2016005351A (es) | Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble | |
| CR20160016A (es) | Pirazolpiridinas sustituidas | |
| CL2014002845A1 (es) | Compuestos derivados de pirazol inhibidores de sglt1; metodo para tratar la diabetes; composicion farmaceutica; uso del compuesto para el tratamiento de la diabetes tipo 1 y tipo 2. | |
| AR110330A1 (es) | Uso de derivados de bencimidazol para escape ácido nocturno | |
| GT201500189A (es) | Inhibidores de autotaxina | |
| CU20150065A7 (es) | Compuestos derivados de bencil 4-((2-(triazol-5-il)acetamido)metil)piperidin-1- carboxilato activos como inhibidores de autotaxina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |